Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

• Status: Completed
• Trial end date: 2006-01-01

Summary

This study will assess the efficacy of subsequent protease inhibitor (PI)-containing therapy in subjects who have acquired HIV-1 protease mutations whilst receiving a GW433908 (fosamprenavir)-containing regimen.

• Phase: Phase 3

Details

• Lead Sponsor: ViiV Healthcare
• Treatments: Fosamprenavir; HIV Protease Inhibitors; Protease Inhibitors; Reverse Transcriptase Inhibitors